Ossiam increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 102.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,583 shares of the medical equipment provider’s stock after acquiring an additional 8,882 shares during the quarter. Ossiam’s holdings in Zimmer Biomet were worth $2,272,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Cutler Group LLC CA acquired a new position in shares of Zimmer Biomet in the 1st quarter valued at $25,000. Clear Street Markets LLC acquired a new position in Zimmer Biomet in the fourth quarter worth $27,000. Orion Capital Management LLC boosted its stake in Zimmer Biomet by 234.7% in the first quarter. Orion Capital Management LLC now owns 251 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 176 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Zimmer Biomet in the first quarter worth $35,000. Finally, Horizon Bancorp Inc. IN bought a new position in shares of Zimmer Biomet in the fourth quarter valued at about $38,000. 87.48% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Zimmer Biomet
In other Zimmer Biomet news, Director Arthur J. Higgins purchased 1,000 shares of the stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $115.61 per share, for a total transaction of $115,610.00. Following the purchase, the director now owns 3,400 shares of the company’s stock, valued at $393,074. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Michael W. Michelson purchased 1,300 shares of the company’s stock in a transaction on Friday, August 25th. The shares were purchased at an average cost of $115.50 per share, with a total value of $150,150.00. Following the completion of the transaction, the director now owns 3,385 shares of the company’s stock, valued at approximately $390,967.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Arthur J. Higgins acquired 1,000 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were purchased at an average price of $115.61 per share, for a total transaction of $115,610.00. Following the completion of the purchase, the director now directly owns 3,400 shares in the company, valued at $393,074. The disclosure for this purchase can be found here. Insiders acquired 5,300 shares of company stock valued at $619,090 in the last ninety days. 0.95% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Zimmer Biomet Stock Up 0.1 %
Shares of ZBH stock opened at $120.65 on Monday. The firm has a fifty day moving average of $129.83 and a 200-day moving average of $131.61. The company has a quick ratio of 0.95, a current ratio of 1.96 and a debt-to-equity ratio of 0.42. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.60 and a 12-month high of $149.25. The company has a market capitalization of $25.21 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 2.37 and a beta of 1.04.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Tuesday, August 1st. The medical equipment provider reported $1.82 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.82. The firm had revenue of $1.87 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 7.03% and a return on equity of 12.36%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.82 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.51 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $0.96 annualized dividend and a dividend yield of 0.80%. Zimmer Biomet’s dividend payout ratio is currently 39.83%.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
- Five stocks we like better than Zimmer Biomet
- Best Stocks Under $5.00
- MarketBeat Week in Review – 9/4 – 9/8
- Do ETFs Pay Dividends? What You Need to Know
- The Best 5 Small Cap AI Companies to Buy Now
- 3 Best Fintech Stocks for a Portfolio Boost
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.